Cargando…

The knowns & unknowns of pulmonary toxicity following immune checkpoint inhibitor therapies: a narrative review

Since their discovery immune checkpoint inhibitors (ICI) have dramatically changed the treatment landscape for many cancers. In addition to their efficacy they are generally well tolerated, however, they have led to a new range of immune-related adverse events (irAEs) including pneumonitis. While no...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miller, Alistair R., Manser, Renee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Review Article on Lung Cancer and The Immune System
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264318/ https://www.ncbi.nlm.nih.gov/pubmed/34295675 http://dx.doi.org/10.21037/tlcr-20-806

Ejemplares similares

Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors
por: Rangamuwa, Kanishka, et al.
Publicado: (2021)

A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer
por: Akanda, Zarique Z., et al.
Publicado: (2021)

Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors
por: Lu, Shun, et al.
Publicado: (2019)

Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies
por: Chen, Xuguang, et al.
Publicado: (2021)

Lung cancer and the immune system—current controversies and future opportunities
por: Steinfort, Daniel P.
Publicado: (2021)

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors
por: Barlesi, Fabrice, et al.
Publicado: (2022)

Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience
por: Altan, Mehmet, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
por: Bylsma, Sophia, et al.
Publicado: (2022)

Increase in tumour PD-L1 expression in non-small cell lung cancer following bronchoscopic thermal vapour ablation
por: Rangamuwa, Kanishka, et al.
Publicado: (2021)

Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy
por: Hsu, Melinda L, et al.
Publicado: (2022)

Immunotherapy in oncogene addicted non-small cell lung cancer
por: McLean, Luke, et al.
Publicado: (2021)

Exploring natural killer cell immunology as a therapeutic strategy in lung cancer
por: Hess, Jonas B., et al.
Publicado: (2021)

Emerging and multifaceted role of neutrophils in lung cancer
por: Aloe, Christian, et al.
Publicado: (2021)

B cells in lung cancer—not just a bystander cell: a literature review
por: Leong, Tracy L., et al.
Publicado: (2021)

Integrating endobronchial ultrasound bronchoscopy with molecular testing of immunotherapy biomarkers in non-small cell lung cancer
por: Bozinovski, Steven, et al.
Publicado: (2021)

Holding our breath: the promise of tissue-resident memory T cells in lung cancer
por: Marceaux, Claire, et al.
Publicado: (2021)

Household disposable income and long-term survival after pulmonary resections for lung cancer
por: Sachs, Erik, et al.
Publicado: (2020)

Prediction of malignancy for solitary pulmonary nodules based on imaging, clinical characteristics and tumor marker levels
por: Hou, Hongjun, et al.
Publicado: (2020)

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
por: Moskovitz, Mor, et al.
Publicado: (2022)

External validation of a convolutional neural network artificial intelligence tool to predict malignancy in pulmonary nodules
por: Baldwin, David R, et al.
Publicado: (2020)

PRIMARY PULMONARY CAVITATING ADENOCARCINOMA IN A PATIENT PRESENTING WITH COVID-19 PNEUMONIA: A CASE REPORT
por: TIJANI, SULAIMAN, et al.
Publicado: (2022)

Virtual bronchoscopic navigation combined with endobronchial ultrasound to diagnose small peripheral pulmonary lesions: a randomised trial
por: Ishida, Takashi, et al.
Publicado: (2011)

Immune checkpoints in chronic obstructive pulmonary disease
por: Wilkinson, Tom M.A.
Publicado: (2017)

An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B(12) and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of severe neutropenic toxicity
por: Minchom, A R, et al.
Publicado: (2014)

White Blood Cells in Patients Treated with Programmed Cell Death-1 Inhibitors for Non-small Cell Lung Cancer
por: Sibille, A., et al.
Publicado: (2021)

The effect of the sympathetic nervous system on splenic natural killer cell activity in mice administered the Lactobacillus pentosus strain S-PT84
por: Izumo, Takayuki, et al.
Publicado: (2013)

Cone beam CT-guided navigation bronchoscopy: a cost-effective alternative to CT-guided transthoracic biopsy for diagnosis of peripheral pulmonary nodules
por: Kops, Stephan E P, et al.
Publicado: (2022)

Assessment of Plasma Proteomics Biomarker’s Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial
por: Silvestri, Gerard A., et al.
Publicado: (2018)

Unifying the known and unknown microbial coding sequence space
por: Vanni, Chiara, et al.
Publicado: (2022)

Application of liquid biopsy-based targeted capture sequencing analysis to improve the precision treatment of non-small cell lung cancer by tyrosine kinase inhibitors
por: Zhang, Lei, et al.
Publicado: (2022)

PD-1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in patients with advanced non-squamous non-small-cell lung cancer: a pooled analysis of three randomised trials
por: Meng, Xiangjiao, et al.
Publicado: (2022)

Incidence of second and higher order smoking-related primary cancers following lung cancer: a population-based cohort study
por: Barclay, Matthew E, et al.
Publicado: (2019)

Hematologic Complications of Immune Checkpoint Inhibitors
por: Davis, Elizabeth J., et al.
Publicado: (2019)

Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study
por: Zhou, Fei, et al.
Publicado: (2022)

Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?
por: Lee, Jiyun, et al.
Publicado: (2020)

Primary pulmonary synovial sarcoma
por: Wang, Weixi, et al.
Publicado: (2022)

When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?
por: Mhanna, Laurent, et al.
Publicado: (2019)

Indocyanine green imaging for pulmonary segmentectomy
por: Yotsukura, Masaya, et al.
Publicado: (2021)

The known knowns, known unknowns, and unknown unknowns of surveys and sleep
por: Shaker, Marcus, et al.
Publicado: (2022)

Is investigation of patients with haemoptysis and normal chest radiograph justified?
por: Thirumaran, M, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_n4cfv1ki6cn97fl3eiguqbh8v9